New Label Warns Against Plavix with CYP2C19 Inhibitors, Raises Questions about Role of Mutations | GenomeWeb

By Turna Ray

The US Food and Drug Administration this week issued a new warning to healthcare providers and patients against the concomitant use of the anti-platelet agent Plavix (clopidogrel) and CYP2C19-inhibiting agents, but the agency simultaneously acknowledged that there are many unanswered questions about the link between Plavix response and CYP2C19 metabolism pending results from ongoing studies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.